Revelation Biosciences

Revelation Biosciences released FY2025 Semi-Annual earnings on August 8, 2025 (EST), with actual revenue of USD 0 and EPS of USD -54.3945

Revelation Biosciences Inc. (NASDAQ: REVB) reported a Q2 2025 net loss of $2.4 million, significantly improved from $8.4 million in Q2 2024. The company's EPS improved from $(246.27) to $(7.01) year-over-year. For the first half of 2025, the net loss was $4.5 million, down from $11.1 million in 2024. As of June 30, 2025, cash and equivalents totaled $5.2 million. The company completed patient dosing in the PRIME Phase 1b study and plans to announce data later this quarter while engaging with the FDA for further development of Gemini.

Revelation Biosciences released FY2025 Semi-Annual earnings on August 8, 2025 (EST), with actual revenue of USD 0 and EPS of USD -54.3945

Brief Summary

Impact of The News

Event Context